Mostly Markets
Subscribe
Stocks/Health Care/Life Sciences Tools & Services

IlluminaILMN

Life Sciences Tools & Services · San Diego, California · In the S&P 500
Solid businessPricier than peers
$235.99−18.64%After hours: $236.54 (+0.23%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 148.3% over 1 year
Illumina over 1 yearDaily close, $, to 30 Oct 2026
$100$200$300Nov2026MarMayJulSep$235.99$100$200$300NovMarJul$235.99
Source: Nasdaq daily closes
Market value$35.63B
Price to earnings40.5x
Forward P/E41.6x
Dividend yield–
Year to date+79.9%
One year+148.3%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$99.01$293.69

Quality and valuation

How Illumina compares with other health care stocks. A description, not a recommendation.

Illumina and 7 life sciences tools & services peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: pricier than most

An average business among health care companies, priced above most of them.

Illumina trades at 41.6 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +5.8% vs +7.8%
  • Keeps more of each sale (gross margin): 67.9% vs 65.3%
  • More profitable (operating margin): 21.2% vs 13.3%
  • Turns more of its sales into cash: 23.3% vs 15.9%
ILMN trades at 41.6x forward earnings, above the sector medianForward p/e, Life Sciences Tools & Services peers
IQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1xIQV19.8xDHR26.5xTMO26.6xA26.6xCRL29.1xWAT29.8xMTD34.1xILMN41.6xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Illumina's SEC filings, through the quarter ending 27 Sep 2026. Hover or tap a bar for its value.

Revenue grew 4.2% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$1.1bnQ3 ’26$0.0bn$0.5bn$1.0bnQ4 ’24Q2 ’25Q4 ’25$1.1bnQ3 ’26
Source: SEC filings
Growth slowed to +4.2% last quarterRevenue growth, year on year, %
0%5%Q4 ’24Q2 ’25Q4 ’254.2%Q3 ’260%5%Q4 ’24Q2 ’25Q4 ’254.2%Q3 ’26
Source: SEC filings
Operating margin was 27.0% last quarterOperating income as a share of revenue, %
0%10%20%Q4 ’24Q2 ’25Q4 ’2527.0%Q3 ’260%10%20%Q4 ’24Q2 ’25Q4 ’2527.0%Q3 ’26
Source: SEC filings
Free cash flow was $1.1 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $m
$0m$100m$200m$300mQ4 ’24Q2 ’25Q4 ’25$379mQ3 ’26$0m$200mQ4 ’24Q2 ’25Q4 ’25$379mQ3 ’26
Source: SEC filings
Last 12 monthsILMNSector median
Revenue growth+5.8%+7.8%
Gross margin67.9%65.3%
Operating margin21.2%13.3%
Free cash flow margin23.3%15.9%
Price to earnings40.5x30.2x

Stories on Illumina

Friday, 30 October
Why it moved

Why Illumina (ILMN) Stock Is Sinking Today

Illumina plunged 19.3% on Friday after third-quarter results that topped profit estimates and raised its 2026 forecast failed to ease worries about slowing growth.

ILMN▼ 19.2%
A glass DNA helix cracking above a lab bench

Similar companies

Life Sciences Tools & Services, by market value.

CompanyPriceTodayYTDValue
TMOThermo Fisher Scientific$697.00−1.72%+20.3%$258B
DHRDanaher$232.23−2.00%+1.4%$163B
AAgilent Technologies$174.87−3.47%+28.5%$49.30B
WATWaters$462.72−3.61%+21.8%$45.46B
IQVIQVIA$267.33−2.81%+18.6%$44.06B
MTDMettler Toledo$1,674.81−2.55%+20.1%$33.56B
CRLCharles River Laboratories$359.41−4.44%+80.2%$17.16B
TECHBio-Techne$72.66−0.07%+23.6%$11.41B